362 related articles for article (PubMed ID: 26934341)
1. N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.
Guardia A; Gulten G; Fernandez R; Gómez J; Wang F; Convery M; Blanco D; Martínez M; Pérez-Herrán E; Alonso M; Ortega F; Rullás J; Calvo D; Mata L; Young R; Sacchettini JC; Mendoza-Losana A; Remuiñán M; Ballell Pages L; Castro-Pichel J
ChemMedChem; 2016 Apr; 11(7):687-701. PubMed ID: 26934341
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery.
Prasad MS; Bhole RP; Khedekar PB; Chikhale RV
Bioorg Chem; 2021 Oct; 115():105242. PubMed ID: 34392175
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
Inturi B; Pujar GV; Purohit MN
Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
Armstrong T; Lamont M; Lanne A; Alderwick LJ; Thomas NR
Bioorg Med Chem; 2020 Nov; 28(22):115744. PubMed ID: 33007556
[TBL] [Abstract][Full Text] [Related]
5. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
Rawat R; Whitty A; Tonge PJ
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
[TBL] [Abstract][Full Text] [Related]
6. Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor.
Martínez-Hoyos M; Perez-Herran E; Gulten G; Encinas L; Álvarez-Gómez D; Alvarez E; Ferrer-Bazaga S; García-Pérez A; Ortega F; Angulo-Barturen I; Rullas-Trincado J; Blanco Ruano D; Torres P; Castañeda P; Huss S; Fernández Menéndez R; González Del Valle S; Ballell L; Barros D; Modha S; Dhar N; Signorino-Gelo F; McKinney JD; García-Bustos JF; Lavandera JL; Sacchettini JC; Jimenez MS; Martín-Casabona N; Castro-Pichel J; Mendoza-Losana A
EBioMedicine; 2016 Jun; 8():291-301. PubMed ID: 27428438
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
He X; Alian A; Ortiz de Montellano PR
Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
[TBL] [Abstract][Full Text] [Related]
9. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
11. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis.
Tonge PJ; Kisker C; Slayden RA
Curr Top Med Chem; 2007; 7(5):489-98. PubMed ID: 17346194
[TBL] [Abstract][Full Text] [Related]
12. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
[TBL] [Abstract][Full Text] [Related]
13. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
[TBL] [Abstract][Full Text] [Related]
14. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
[TBL] [Abstract][Full Text] [Related]
15. Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations.
Stigliani JL; Bernardes-Génisson V; Bernadou J; Pratviel G
Org Biomol Chem; 2012 Aug; 10(31):6341-9. PubMed ID: 22751934
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
Subba Rao G; Vijayakrishnan R; Kumar M
Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
Lu XY; You QD; Chen YD
Mini Rev Med Chem; 2010 Mar; 10(3):181-92. PubMed ID: 20408801
[TBL] [Abstract][Full Text] [Related]
18. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
[TBL] [Abstract][Full Text] [Related]
19. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
